Ingenus Pharmaceuticals has received FDA approval for the Abbreviated New Drug Application (ANDA 215571) targeting albuterol sulfate inhalation powder, positioning the company to secure additional market share amid increasing demand for cost-effective respiratory solutions. This regulatory clearance enables the manufacturer to compete aggressively with branded drugs, offering an affordable alternative for widely used asthma and COPD treatments.